江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）的股票自 2025 年 2 月 27 日至 4 月 2 日期间，已满足连续三十个交易日中至少有十五个交易日 的收盘价不低于"诺泰转债"当期转股价格（42.23 元/股）的 130%（含 130%， 即 54.899 元/股），根据《江苏诺泰澳赛诺生物制药股份有限公司向不特定对象 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，已触发 "诺泰转债"的有条件赎回条款。 （二）本次可转债赎回事项公告披露情况 公司于 2025 年 4 月 2 日召开第三届董事会第二十五次会议审议通过了《关 于提前赎回"诺泰转债"的议案》，决定行使"诺泰转债"的提前赎回权，对"赎 回登记日"登记在册的"诺泰转债"全部赎回。具体内容详见公司于 2025 年 4 月 3 日在上海证券交易所网站（www.sse.com.cn）披露的《江苏诺泰澳赛诺生物 制药股份有限公司关于提前赎回"诺泰转债"的公告》（公告编号：2025-018）。 证券代码：688076 证券简称：诺泰生物 公告编号：2025-040 江苏诺泰澳赛诺生物制药股份有限公司 关于"诺泰转债"赎回结果暨股 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [8] Core Views - The company reported a revenue of 1.625 billion yuan in 2024, representing a year-on-year growth of 57.21%, and a net profit attributable to shareholders of 404.39 million yuan, which is an increase of 148.19% [8] - The revenue from the self-selected product segment grew significantly, with the peptide API segment achieving a revenue of 948 million yuan, up 127.72% [8] - The custom products segment maintained a high growth rate, with revenue reaching 494 million yuan, an increase of 22.34% [8] - The company is expected to benefit from the high demand in the peptide API industry, with projected net profits of 5.59 billion yuan in 2025 and 7.11 billion yuan in 2026 [8] Financial Summary - Total revenue forecast for 2023A is 1.034 billion yuan, increasing to 4.278 billion yuan by 2027E, with a compound annual growth rate (CAGR) of 37.74% [8] - The net profit attributable to shareholders is expected to grow from 162.94 million yuan in 2023A to 872.54 million yuan in 2027E, reflecting a CAGR of 22.74% [8] - The latest diluted EPS is projected to rise from 0.74 yuan in 2023A to 3.97 yuan in 2027E [8] - The current P/E ratio is 29.46 for 2024A, decreasing to 13.65 by 2027E [8]

Investment Rating - The report maintains a "Recommended" rating for the company [4][7]. Core Views - The company achieved a revenue of 1.63 billion yuan in 2024, representing a year-on-year growth of 57.2%, and a net profit attributable to shareholders of 400 million yuan, up 148.2% year-on-year [1]. - For Q1 2025, the company reported a revenue of 570 million yuan, a 59.0% increase year-on-year, and a net profit of 150 million yuan, reflecting a growth of 130.1% year-on-year [1]. - The revenue structure is continuously optimized, with customized products and technical services generating 490 million yuan in revenue (up 22.3% year-on-year) and a gross margin of 56.2% [2]. - The raw material drug and intermediate business saw a revenue of 940 million yuan, a significant increase of 127.0% year-on-year, with a gross margin of 76.7% [3]. - The CDMO/CMO business generated 470 million yuan in revenue, growing by 21.0% year-on-year, with a gross margin of 55.9% [4]. - The formulation business experienced a revenue decline of 13.4% year-on-year, but new products are expected to drive growth in 2025 [4]. - The company is projected to achieve net profits of 540 million yuan, 700 million yuan, and 900 million yuan for 2025, 2026, and 2027, respectively, with corresponding year-on-year growth rates of 32.5%, 30.0%, and 28.6% [4]. Summary by Sections Financial Performance - In 2024, the company reported total revenue of 1.63 billion yuan and a net profit of 404 million yuan, with significant growth rates of 57.2% and 148.2% respectively [1][6]. - For Q1 2025, the company achieved a revenue of 570 million yuan and a net profit of 150 million yuan, marking year-on-year growth of 59.0% and 130.1% [1]. Revenue Structure - The customized products and technical services segment generated 490 million yuan in revenue, while the self-selected products segment achieved 1.13 billion yuan, reflecting a year-on-year growth of 79.5% [2]. - The overall gross margin improved, reaching 62.2% in Q4 2024 and 70.2% in Q1 2025 [2]. Business Segments - The raw material drug business reported a revenue of 940 million yuan, with a gross margin of 76.7%, driven by strong order expansion and capacity release [3]. - The CDMO/CMO business generated 470 million yuan in revenue, with a focus on major disease treatment areas and partnerships with well-known international pharmaceutical companies [4]. - The formulation segment's revenue declined to 180 million yuan, but new product registrations are expected to revitalize growth [4]. Future Projections - The company forecasts net profits of 540 million yuan in 2025, with a year-on-year growth rate of 32.5%, and further growth expected in subsequent years [4][6].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 54.21 CNY [7]. Core Insights - The company achieved a revenue of 1.63 billion CNY in 2024, representing a year-on-year growth of 57.2%, and a net profit attributable to shareholders of 400 million CNY, up 148.2% [1]. - For Q1 2025, the company reported a revenue of 570 million CNY, a 59.0% increase year-on-year, with a net profit of 150 million CNY, reflecting a growth of 130.1% [1]. - The revenue structure is continuously optimizing, with custom products and technical services generating 490 million CNY in 2024, a 22.3% increase, and a gross margin of 56.2% [2]. - The raw material drug and intermediate business saw a revenue of 940 million CNY in 2024, a significant increase of 127.0%, with a gross margin of 76.7% [3]. - The CDMO/CMO business generated 470 million CNY in revenue, growing by 21.0%, with a gross margin of 55.9% [4]. - The formulation business experienced a decline in revenue to 180 million CNY, down 13.4%, but new products are expected to drive growth in 2025 [4]. - The company forecasts net profits of 540 million CNY, 700 million CNY, and 900 million CNY for 2025, 2026, and 2027, respectively, with corresponding growth rates of 32.5%, 30.0%, and 28.6% [4]. Summary by Sections Financial Performance - In 2024, the company reported total revenue of 1.63 billion CNY and a net profit of 400 million CNY, with significant growth rates of 57.2% and 148.2% respectively [1][6]. - For Q1 2025, the revenue was 570 million CNY, with a net profit of 150 million CNY, indicating strong performance [1]. Revenue Structure - The custom products and technical services segment generated 490 million CNY in 2024, while the self-selected products segment achieved 1.13 billion CNY, marking a 79.5% increase [2]. - The overall gross margin improved to 62.2% in Q4 2024 and 70.2% in Q1 2025 [2]. Business Segments - The raw material drug business reported a revenue of 940 million CNY in 2024, with a gross margin of 76.7% [3]. - The CDMO/CMO segment achieved 470 million CNY in revenue, with a focus on major disease treatments [4]. - The formulation segment's revenue declined to 180 million CNY, but new product registrations are expected to revitalize growth [4]. Future Projections - The company anticipates net profits of 540 million CNY in 2025, with a growth rate of 32.5%, and further growth in subsequent years [4][6].

Group 1: Tianqi Materials - Tianqi Materials reported that the impact of the US tariff policy is minimal, with direct sales to the US accounting for approximately 1% of total revenue in 2024 [1] - The company is actively promoting local production capacity in the US, collaborating with Honeywell to establish a joint venture for the large-scale production of electrolytes and lithium hexafluorophosphate in North America [1] - The addition ratio of LIFSI in electrolytes is expected to be around 1.9% in 2024, with increasing usage in fast-charging battery electrolyte formulations [1] - PEEK materials are currently in the product trial verification stage, primarily used for modifying materials in battery cell structural components [1] - The company launched a 5V electrolyte system in March, which features high safety and stability, and is accelerating customer verification [1] - A lithium sulfide route for solid electrolytes is under trial production, and the company has solutions and technical reserves for sodium-ion battery electrolytes, with existing production lines capable of rapid material system switching [1] - The company has a significant cost advantage with a production capacity of 330,000 tons for precursor iron phosphate, and the third-generation iron phosphate products are in the customer verification stage [1] - In the coming years, domestic capacity expansion will slow down, with a focus shifting towards overseas markets [1] Group 2: Nuotai Biological - Nuotai Biological reported a main revenue of 566 million yuan for Q1 2025, representing a year-on-year increase of 58.96% [2] - The net profit attributable to shareholders reached 153 million yuan, up 130.1% year-on-year [2] - The net profit after deducting non-recurring items was 152 million yuan, reflecting a 131.79% increase compared to the previous year [2] - The company's debt ratio stands at 47.86%, with investment income of 647,500 yuan and financial expenses of 8.2452 million yuan [2] - The gross profit margin is reported at 70.2% [2]

Core Viewpoint - Duorui Pharmaceutical (301075.SZ) reported its first annual loss since going public, with total revenue of 241 million yuan, a year-on-year decline of 28.02%, and a net profit attributable to shareholders of -62.67 million yuan, marking a staggering decline of 432.44% from profit to loss [2] Group 1: Financial Performance - The company's core product, sodium acetate Ringer's injection, which previously accounted for over 90% of revenue, saw sales plummet from 465 million yuan in 2021 to less than 120 million yuan in 2024, a nearly 50% year-on-year decline [3] - The decline in sales was primarily due to the product being selected in the 10th batch of national drug procurement, resulting in a significant drop in the bidding price [3] - Operating cash flow for 2024 was -67.18 million yuan, a drastic decrease of 641.19% year-on-year, mainly due to reduced sales revenue [6] Group 2: Strategic Challenges - The company is heavily reliant on a single core product, which exposes it to risks in a changing policy environment characterized by medical insurance cost control and normalized bulk procurement [3] - Duorui Pharmaceutical's acquisition of a 70% stake in Shanghai Jianling for 271 million yuan, which included debt compensation, is seen as a key move towards transforming into high-end raw materials, but the acquisition came with a high premium of 1182% [4] - The company’s cash reserves were significantly impacted by the acquisition, leaving only 110 million yuan in cash and equivalent, while short-term and long-term borrowings reached 25.02 million yuan and 18.8 million yuan, respectively [4] Group 3: R&D and Diversification Efforts - In an attempt to diversify revenue sources, the company has been exploring agency business and new drug development, with sales from its agency product, amoxicillin sodium and clavulanate potassium injection, reaching 19.57 million yuan, accounting for 13.01% of total revenue [6] - R&D investment increased by 54.21% in 2024 to 37.00 million yuan, representing 15.38% of revenue, but the low conversion efficiency is a concern, as the net profit excluding non-recurring items dropped by 1365.6% [6] - The company aims to accelerate the commercialization of intermediate and peptide raw material projects and develop derivatives of sodium acetate Ringer's injection, but the success of these strategies depends on the integration efficiency of acquired assets and the speed of new product pipeline development [7]

医药生物/化学制药 诺泰生物（688076.SH） 业绩表现持续亮眼，看好多肽原料药龙头全年机会 2025 年 04 月 24 日 投资评级：买入（维持） | 日期 | 2025/4/23 | | --- | --- | | 当前股价(元) | 53.15 | | 一年最高最低(元) | 81.50/41.80 | | 总市值(亿元) | 119.38 | | 流通市值(亿元) | 119.38 | | 总股本(亿股) | 2.25 | | 流通股本(亿股) | 2.25 | | 近 3 个月换手率(%) | 133.89 | 股价走势图 数据来源：聚源 -16% 0% 16% 32% 48% 2024-04 2024-08 2024-12 2025-04 诺泰生物 沪深300 相关研究报告 《GLP-1 原料药已进入商业化供货阶 段，看好赛道龙头全年机会—公司信 息更新报告》-2025.3.5 《前三季度业绩维持高增长，多肽 API 业务持续发力—公司信息更新报告》 -2024.10.24 《业绩持续高增长，十吨级多肽新产 能预计提前落地—公司信息更新报 告》-2024.8.26 余汝意（分析师） 汪晋（联 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown impressive performance with a revenue of 1.625 billion yuan in 2024, representing a year-on-year growth of 57.21%. The net profit attributable to the parent company reached 404 million yuan, up 148.19% year-on-year [4] - In Q1 2025, the company achieved a revenue of 566 million yuan, marking a year-on-year increase of 58.96% and a quarter-on-quarter growth of 51.82%. The net profit attributable to the parent company was 153 million yuan, reflecting a year-on-year growth of 130.10% and a quarter-on-quarter increase of 181.88% [4] - The company is expected to benefit from the commercial supply phase of GLP-1 raw materials, with anticipated orders due to its compliance, high-quality products, and large batch delivery capabilities [4] Financial Performance Summary - In 2024, the company's raw material drug business generated revenue of 944 million yuan, a year-on-year increase of approximately 127%. By the end of 2024, the company had obtained domestic registration for 21 raw material drug varieties and FDA DMF/VMF numbers for 15 varieties [5] - The CDMO business achieved revenue of 494 million yuan in 2024, a year-on-year growth of about 22.33%. The formulation business generated 184 million yuan, experiencing a decline of 13.38% [6] - The company forecasts net profits of 526 million yuan, 691 million yuan, and 873 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 2.34, 3.08, and 3.89 yuan [4][8] Valuation Metrics - The current stock price is 53.15 yuan, with a market capitalization of 11.938 billion yuan. The stock has a P/E ratio of 22.7 for 2025, 17.3 for 2026, and 13.7 for 2027 [1][8] - The company’s gross margin is projected to be 65.5% in 2025, with a net margin of 24.3% [8]

诺泰生物 2025042320250416 摘要 • 诺泰生物 2025 年第一季度营收 5.66 亿元，同比增长 59%；净利润 1.53 亿元，同比增长 130%；扣非净利润 1.52 亿元，同比增长 132%，延续 了 2024 年营收同比增长 143%的增长态势，显示出强劲的增长势头。 • 公司通过践行平台战略，将新兴技术动态运用到细分板块，在合成生物学、 基因治疗等前沿技术平台积极布局，并拓展延伸至核酸药物、环肽和 XDC，实现技术优势叠加，从而保持技术领先。 • 诺泰生物第四代规模化吨级多肽车间正式投产，多肽产能每年 5 吨，多条 生产线通过药品 GMP 符合性检查，替尔泊泰和利拉鲁肽原料药生产线通 过欧盟 GMP 符合性检查，并通过美国 FDA 的 CGMP 现场检查，成为行业 领先企业。 • 公司设立专项小组监测全球生物医药行业监管政策变动，通过地缘政治情 景预演动态模拟应对方案，灵活贸易安排降低关税影响，成本效率革命技 术降低生产成本，客户弹性定价策略锁定合理利润率，深化 ESG 价值构建 巩固欧美客户合作。 Q&A 诺泰生物在 2024 年的业绩表现如何？2025 年第一季度的业绩情况如何 ...

Core Insights - The company, Nuotai Biopharmaceuticals, reported strong financial performance with a revenue of 1.625 billion yuan in 2024, a year-on-year increase of 57.21%, and a net profit of 404 million yuan, up 148.19% [1] - In Q1 2025, the company continued its growth trend with revenues of 566 million yuan and a net profit of 153 million yuan, reflecting year-on-year increases of 58.96% and 130.10% respectively [1] - The company announced significant cash dividends, proposing a distribution of 1.76 billion yuan in cash dividends and a stock bonus, which represents 48.91% of the annual net profit [1] Financial Performance - In 2024, the company's self-selected product revenue grew by 79.49% to 1.129 billion yuan, while foreign revenue increased by 129.22% to 1.026 billion yuan [3] - The total cash dividends for the year are expected to reach 198 million yuan, with a mid-year dividend of 1 yuan per 10 shares and a year-end proposal of 8 yuan per 10 shares plus a stock bonus of 4 shares [1] Market Demand and Positioning - The global demand for GLP-1 peptide drugs, including liraglutide and semaglutide, has been robust, contributing to the company's strong performance [2] - The global peptide drug market has expanded significantly, growing from approximately 12.39 billion USD in 2007 to 43 billion USD in 2020, with an annual growth rate of 16% [2] R&D and Innovation - The company increased its R&D investment by 178.24% in 2024, reaching 372 million yuan, which constitutes 22.88% of its revenue [5] - The R&D team expanded to 385 members, with a 44.94% proportion of master's and doctoral degree holders [5] - The company has 43 projects under development, focusing on diabetes, cardiovascular diseases, and tumors, with several products achieving regulatory milestones [6] Production Capacity and Expansion - The company has completed the construction of its fourth-generation large-scale peptide production facility, achieving an annual capacity of 5 tons [7] - A new oligonucleotide production facility is under construction, expected to be completed by October 2025, with a projected capacity of 1,000 kg per year [7] Strategic Initiatives - The company is implementing a dual strategy of "technical depth + industrial synergy" to build a competitive advantage in the global market [8] - It plans to establish an international industrial safety network and strategically acquire overseas production bases to mitigate geopolitical risks [8][9] - The company is actively monitoring global biopharmaceutical regulatory changes and expanding its business footprint into emerging markets such as Latin America and the Middle East [9]